ArticleScience translational medicine2017
Resveratrol for Alzheimer's disease?
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Mediterranean Diet, Polyphenols, and Neuroprotection: Mechanistic Insights into Resveratrol and Oleuropein.Nutrients · 2025Review
- Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles.Acta pharmaceutica Sinica. B · 2022Review
- Integrating network pharmacology analysis and pharmacodynamic evaluation for exploring the active components and molecular mechanism of moutan seed coat extract to improve cognitive impairment.Frontiers in pharmacology · 2022Article
- SIRT1 Is Involved in the Neuroprotection of Pterostilbene Against Amyloid β 25-35-Induced Cognitive Deficits in Mice.Frontiers in pharmacology · 2022Article
- The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer's Disease.Cells · 2021Review
- Therapeutic potentials of resveratrol in combination with radiotherapy and chemotherapy during glioblastoma treatment: a mechanistic review.Cancer cell international · 2021Review
- Personalizing the Care and Treatment of Alzheimer's Disease: An Overview.Pharmacogenomics and personalized medicine · 2021Review
- The Plant-Derived Compound Resveratrol in Brain Cancer: A Review.Biomolecules · 2020Review
- Natural Compounds as Inhibitors of Aβ Peptide Aggregation: Chemical Requirements and Molecular Mechanisms.Frontiers in neuroscience · 2020Review
- Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment.Frontiers in pharmacology · 2018Review
- Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease.Nutrients · 2017Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol modulates β-amyloid levels and inflammatory markers in patients with Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.